Author

admin

Browsing

Sun Summit Minerals Corp. (TSXV: SMN,OTC:SMREF) (OTCQB: SMREF) (‘Sun Summit’ or the ‘Company’) is pleased to announce that it will be attending and presenting at the 51st Annual New Orleans Investment Conference, taking place November 2–5, 2025 at the Hilton New Orleans Riverside.

Niel Marotta, CEO and Director, will host a Sunrise Session presentation on Tuesday, November 4 at 7:15 AM (Churchill B2), where he will share updates on the Company’s flagship JD Project in British Columbia’s Toodoggone District, following the completion of a successful 2025 exploration season.

Space is limited. Investors are invited to RSVP by October 31 to info@sunsummitminerals.com, and to visit Sun Summit at Booth #229 throughout the conference.

The New Orleans Investment Conference brings together leading analysts, newsletter writers, and investors to discuss emerging opportunities across all major asset classes. Register today at https://neworleansconference.com/online-registration/.

About the JD Project

The JD Project is located in the Toodoggone mining district in north-central British Columbia, a highly prospective deposit-rich mineral trend. The project covers an area of over 15,000 hectares and is in close proximity to active exploration and development projects, such as Thesis Gold’s Lawyers and Ranch projects, TDG Gold’s Baker-Shasta projects, Amarc Resource’s AuRORA project, Centerra’s Gold’s Kemess East and Underground projects, as well as the past-producing Kemess open pit copper-gold mine.

The project is 450 kilometres northwest of the city of Prince George, and 25 kilometres north of the Sturdee airstrip. It is proximal to existing infrastructure in place to support the past-producing Kemess mine, including roads and a hydroelectric power line.

The JD Project is in a favourable geological environment characterized by both high-grade epithermal gold and silver mineralization, as well as porphyry-related copper and gold mineralization. Some historical exploration, including drilling, geochemistry and geophysics, has been carried out on the property, however the project area is largely underexplored.

About Sun Summit

Sun Summit Minerals (TSXV: SMN,OTC:SMREF) (OTCQB: SMREF) is a mineral exploration company focused on the discovery, expansion and advancement of district-scale gold and copper assets in British Columbia. The Company’s diverse portfolio includes its flagship JD Project and the nearby Theory Project in the Toodoggone region of north-central B.C., as well as the Buck Project in central B.C.

Further details are available at www.sunsummitminerals.com.

On behalf of the board of directors

Niel Marotta
Chief Executive Officer & Director
info@sunsummitminerals.com

For further information, contact:

Matthew Benedetto, Simone Capital
mbenedetto@simonecapital.ca
Tel. 416-817-1226

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Statements contained in this news release that are not historical in nature may be ‘forward-looking information’ within the meaning of applicable Canadian securities legislation (‘forward-looking statements ‘), which involve risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements, by their nature, require Sun Summit to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Forward-looking statements are not guarantees of performance. Words such as ‘may’, ‘will’, ‘would’, ‘could’, ‘expect’, ‘believe’, ‘plan’, ‘anticipate’, ‘intend’, ‘estimate’, ‘continue’, ‘objective’, ‘strategy’, or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are intended to identify forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including the assumptions, qualifications, limitations or statements relating to the pending results of the drill holes, the success of the exploration program, the impressive results of the drill campaign, the ability of exploration activities (including drilling) to accurately predict mineralization, future drill programs and high-priority targets, our timing and ability to receive assay results, the reliability of historical information that cannot be independently verified by Sun Summit, interests in the JD Project, errors in geological modelling, and the adjacent properties having any significance to the projects in which Sun Summit has an interest. There is significant risk that the forward-looking statements will not prove to be accurate, that the management’s assumptions may not be correct and that actual results may differ materially from such forward-looking statements. These forward-looking statements are based on a number of assumptions which may prove to be incorrect which, without limiting the generality of the following, include: the Company’s ability to obtain assay results for the completed drill program; the anticipated results varying from current indications, including the already released drill results; risks inherent in exploration activities; volatility and sensitivity to market prices; volatility and sensitivity to capital market fluctuations; and fluctuations in metal prices. Accordingly, readers should not place undue reliance on the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof or the dates specifically referenced in this news release, where applicable. Except as required by applicable securities laws and regulation, Sun Summit disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. All forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271649

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES./

Quimbaya Gold Inc. (‘Quimbaya’ or the ‘Company’) (CSE: QIM,OTC:QIMGF) (OTCQB: QIMGF) (FSE: K05) is pleased to announce that it has entered into an agreement with Stifel Canada to act as sole underwriter and bookrunner (the ‘Underwriter’), in connection with a ‘bought deal’ private placement of 14,300,000 units of the Company  (the ‘LIFE Units’) at a price of C$0.70 per LIFE Unit (the ‘Offering Price’) for aggregate gross proceeds of C$10,010,000 (the ‘Offering’), with the LIFE Units to be issued pursuant to the Listed Issuer Financing Exemption (as defined below). 

The Company has granted to the Underwriter an option, exercisable up to 48 hours prior to the closing date, to purchase for resale up to an additional 15% of LIFE Units at the Offering Price for additional gross proceeds of up to C$1,501,500

Each LIFE Unit will consist of one common share (a ‘Common Share‘) and one-half (½) of one Common Share purchase warrant (each whole warrant, a ‘Warrant‘) of the Company. Each Warrant will be exercisable to acquire one Common Share for a period of 36 months following the closing date of the Offering at an exercise price of C$1.00 per common share.

The net proceeds from the Offering are expected to be used to advance the Company’s exploration programs, including drilling at the Tahami South project and follow-up work on regional copper-gold and gold targets, as well as for general working capital.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (‘NI 45-106‘), the LIFE Units will be offered for sale to purchasers resident in Canada other than Quebec and/or other qualifying jurisdictions pursuant to the listed issuer financing exemption under Part 5A of NI 45-106 (the ‘Listed Issuer Financing Exemption‘). Because the Offering is being completed pursuant to the Listed Issuer Financing Exemption, the LIFE Units issued pursuant to the Offering will not be subject to a hold period pursuant to applicable Canadian securities laws. There is an offering document related to the Offering that can be accessed under the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and on the Company’s website at quimbayagold.com. Prospective investors should read the offering document before making an investment decision.

The Offering is scheduled to close on or about November 4, 2025 (the ‘Closing Date‘) and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals including the acceptance of the Canadian Securities Exchange.

The securities referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the ‘U.S. Securities Act‘), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, ‘U.S. Persons’ (as such term is defined in Regulation S under the U.S. Securities Act) absent such registration or an applicable exemption from the registration requirements of the U.S. Securities Act. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.

About Quimbaya 

Quimbaya aims to discover gold resources through exploration and acquisition of mining properties in the prolific gold mining districts of Colombia. Managed by an experienced team in the mining sector, Quimbaya is focused on three projects in the regions of Segovia (Tahami Project), Puerto Berrio (Berrio Project), and Abejorral (Maitamac Project), all located in Antioquia Province, Colombia.

Quimbaya Gold Inc.

Follow on X @quimbayagoldinc
Follow on LinkedIn @quimbayagold
Follow on YouTube @quimbayagoldinc
Follow on Instagram @quimbayagoldinc
Follow on Facebook @quimbayagoldinc

Cautionary Statements

Certain statements contained in this press release constitute ‘forward-looking information’ as that term is defined in applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. Generally, but not always, forward-looking statements and information can be identified by the use of forward-looking terminology such as ‘intends’, ‘expects’ or ‘anticipates’, or variations of such words and phrases or statements that certain actions, events or results ‘may’, ‘could’, ‘should’, ‘would’ or ‘occur’. Forward-looking statements herein include statements and information regarding the closing of the Offering, Offering’s intended use of proceeds, any exercise of Warrants, the future plans for the Company, including any expectations of growth or market momentum, future expectations for the gold sector generally, the Colombian gold sector more particularly, or how global or local market trends may affect the Company, intended exploration on any of the Company’s properties and any results thereof, the strength of the Company’s mineral property portfolio, the potential discovery and potential size of the discovery of minerals on any property of the Company’s, including Tahami South, the aims and goals of the Company, and other forward-looking information. Forward-looking information by its nature is based on assumptions and involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Quimbaya to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. These assumptions include, but are not limited to, that the Company’s exploration and other activities will proceed as expected. The future outcomes that relate to forward-looking statements may be influenced by many factors, including but not limited to: future planned development and other activities on the Company’s mineral properties; an inability to finance the Company; obtaining required permitting on the Company’s mineral properties in a timely manner; any adverse changes to the planned operations of the Company’s mineral properties; failure by the Company for any reason to undertake expected exploration programs; achieving and maintaining favourable relationships with local communities; mineral exploration results that are poorer or better than expected; prices for gold remaining as expected; currency exchange rates remaining as expected; availability of funds for the Company’s projects; prices for energy inputs, labour, materials, supplies and services (including transportation); no labour-related disruptions; no unplanned delays or interruptions in scheduled construction and production; all necessary permits, licenses and regulatory approvals are received in a timely manner; the Offering proceeds being received as anticipated; all requisite regulatory and stock exchange approvals for the Offering are obtained in a timely fashion; investor participation in the Offering; and the Company’s ability to comply with environmental, health and safety laws. Although Quimbaya’s management believes that the assumptions made and the expectations represented by such information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. Furthermore, should one or more of the risks, uncertainties or other factors materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements or information. Readers are cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Quimbaya as of the date of this news release and, accordingly, is subject to change after such date. Except as required by law, Quimbaya does not expect to update forward-looking statements and information continually as conditions change.

SOURCE Quimbaya Gold Inc.

View original content: http://www.newswire.ca/en/releases/archive/October2025/23/c7762.html

News Provided by Canada Newswire via QuoteMedia

This post appeared first on investingnews.com

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.

Read on to learn what’s been driving these Canadian biotech firms.

1. Eupraxia Pharmaceuticals (TSX:EPRX)

Year-on-year gain: 141.23 percent
Market cap: C$410.85 million
Share price: C$8.25

Eupraxia Pharmaceuticals is developing clinical candidates that employ its DiffuSphere technology, which delivers treatments to the targeted tissues.

The company’s candidates are currently EP-104GI for eosinophilic esophagitis and EP-104IAR for knee osteoarthritis, and it is exploring the use of its technology for other active compounds as well.

Eupraxia added EP-104GI to its pipeline through its acquisition of EpiPharma Therapeutics in late 2023. The company has continued to advance the treatment through clinical trials in 2025 and released multiple rounds of positive data from its Phase 1b/2a trial cohorts.

In July, Eupraxia dosed its first patient after advancing its investigation to Phase 2b trials based on safety and efficacy data from the earlier Phase 2a patient cohorts. Top-line results from the Phase 2b study are anticipated in the second half of 2026.

In September, the company shared data from the highest-dose cohort of the still ongoing Phase 1b/2a trials, reporting that the group saw the largest improvements so far.

2. Bright Minds Biosciences (CSE:DRUG)

Year-on-year gain: 103.17 percent
Market cap: C$683.67 million
Share price: C$92.95

Bright Minds Biosciences is developing novel serotonin agonists targeting neurocircuit abnormalities linked to neuropsychiatric disorders and epilepsy, designing next-generation treatments that aim to retain the therapeutic benefits of psychedelics while minimizing side effects.

Its lead candidate, BMB-101, a selective 5-HT2C receptor agonist, has shown encouraging preclinical efficacy by stopping seizures in an epilepsy mouse model, evaluated jointly with Firefly Neuroscience (NASDAQ:AIFF).

The company’s stock surged nearly 1,500 percent in October 2024 following H. Lundbeck’s acquisition announcement of a competitor focused on similar targets. Strengthening its epilepsy expertise, Bright Minds expanded its scientific advisory board in early 2025 by adding five leaders in the field.

Ongoing clinical progress and strategic growth initiatives position Bright Minds as a promising contender in the neuropsychiatric treatment landscape.

3. Hemostemix (TSXV:HEM)

Year-on-year gain: 31.25 percent
Market cap: C$18.40 million
Share price: C$0.11

Hemostemix is a clinical-stage biotech company focused on developing autologous stem cell therapies, meaning the treatments use a patient’s own cells to theoretically enhance safety and efficacy.

Its main product, ACP-01, is an autologous cell therapy designed to promote tissue repair and regeneration in areas affected by diseases, including a range of heart diseases.

The company announced its first advanced sales orders for ACP-01 in Q1 2025 and has been working to expand internationally and attract new investment.

Hemostemix secured the regulatory green light for commercial sales in Florida after the state passed Senate Bill 1768. The bill creates a framework in which healthcare providers can administer stem cell therapies that had not yet been approved by the US Food and Drug Administration (FDA) but meet the bill’s guidelines.

The company now offers commercial ACP-01 treatments for ischemic pain in the state under the name VesCell, with sales forecasted to reach C$22.5 million in 2026. Operational plans target cash flow positivity by Q4 2026, supported by a growing physician network and commercial pipeline.

Additionally, Hemostemix is currently collaborating with Firefly Neuroscience on a Phase 1 clinical trial of ACP-01 for vascular dementia.

4. NervGen (TSXV:NGEN)

Year-on-year gain: 79.92 percent
Market cap: C$300.97 million
Share price: C$4.39

NervGen is a clinical-stage Canadian biotechnology company that focuses on developing innovative treatments to enable the nervous system to repair itself following damage from injury or disease.

The company’s core technology targets a mechanism that hinders nervous system repair. When the nervous system is damaged, chondroitin sulfate proteoglycans (CSPG) form a “scar.” Initially, CSPGs help contain damage, but their long-term interaction with the PTPσ receptor inhibits repair.

NervGen’s lead drug candidate, NVG-291, is designed to relieve these inhibitory effects to promote nervous system repair. It received fast-track designation from the US FDA.

NervGen is advancing NVG-291 in a Phase 1b/2a clinical trial for spinal cord injury (SCI) and reported positive data from the chronic cohort in June.

NVG-300, a newer preclinical candidate, is being evaluated for ischemic stroke and SCI.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

President Donald Trump is ‘not interested’ in making peace with Colombian President Gustavo Petro, the White House said Thursday, as tensions between Washington and Bogotá continue to escalate.

‘I don’t think we’re seeing de-escalation from the unhinged leader of Colombia right now,’ press secretary Karoline Leavitt told reporters during a White House briefing when asked what Petro could do to reduce tensions.

‘I don’t think the president, frankly, is interested in that at this point,’ Leavitt added.

Relations between the two countries have sharply deteriorated after Petro accused the U.S. of killing innocent fishermen during strikes targeting narco-traffickers in the Caribbean.

Following Petro’s accusation, Trump announced plans to cut off all counter-narcotics aid to Colombia and impose new tariffs on the country.

Trump lashed out at his South American counterpart, calling him a ‘thug’ who is ‘making a lot of drugs.’

‘They’re doing very poorly, Colombia. They make cocaine. They have cocaine factories … and he better watch it or we’ll take very serious action against him and his country,’ Trump said. ‘What he has led his country into is a death trap.’

Petro fired back, threatening to sue Trump in U.S. court.

‘From the slanders that have been cast against me in the territory of the United States by high-ranking officials, I will defend myself judicially with American lawyers in the American justice system,’ Petro wrote on X. ‘I will always stand against genocides and murders by those in power in the Caribbean.’

‘When our help is required to fight against drug trafficking, American society will have it. We will fight against the drug traffickers with the states that want our help,’ he added.

Petro has sought closer ties with Venezuelan dictator Nicolás Maduro while distancing Colombia — a major non-NATO ally — from the United States.

Meanwhile, the U.S. has conducted eight strikes on vessels believed to be transporting narcotics from Latin America. The world is now watching to see whether Trump will follow through on threats to strike Venezuelan soil — or even target Maduro himself, directly or indirectly.

Trump confirmed that he had authorized the CIA to conduct covert operations inside Venezuela and also warned Colombia could face similar consequences.

‘Petro, a low rated and very unpopular leader, with a fresh mouth toward America, better close up these killing fields immediately,’ Trump wrote on Truth Social, ‘or the United States will close them up for him, and it won’t be done nicely.’

In a statement to Fox News Digital, the Colombian Embassy in Washington sought to ease tensions, saying the U.S. representative in Bogotá recently met with Petro and that ‘both sides agreed to continue dialogue in a spirit of cooperation and mutual respect. The meeting reaffirmed the shared commitment towards efforts against illicit drug trafficking, grounded in accuracy, coordination, and security.’

This post appeared first on FOX NEWS

Mayor Eric Adams formally endorsed former Gov. Andrew Cuomo to replace him as the next mayor of New York City on Thursday, less than one month after Adams suspended his re-election campaign.

The endorsement followed Wednesday night’s final mayoral debate, where Cuomo, who is running as an Independent, faced off against Democratic nominee Zohran Mamdani and Republican candidate Curtis Sliwa. Rather than speak to reporters after the debate, Cuomo dashed off to Madison Square Garden to watch the end of the New York Knicks game courtside with Adams.

‘I’m fighting for the family of New York,’ Adams said. ‘That’s why I’m here today, to endorse Andrew Cuomo, to be part of this fight, and I’m going to give him my all these next few days to make sure that Black and Brown communities, specifically, who have believed there’s nothing at stake in this election for them. It is.’

‘Am I angry that I’m not the one taking down Zohran, the socialist and the communist?’ Adams said, eliciting President Donald Trump’s moniker for Mamdani. ‘You’re darn right I am. But, you know what, the city means more to me than anything, and it is time for us as a family to come together.’

‘Today confirms what we’ve long known: Andrew Cuomo is running for Eric Adams’ second term,’ Mamdani said in a statement Thursday. ‘It’s no surprise to see two men who share an affinity for corruption and Trump capitulation align themselves at the behest of the billionaire class and the president himself. We are going to turn the page on the politics of big money and small ideas that these two disgraced executives embody and build a city every New Yorker can afford.’

Mamdani reiterated his criticism of the endorsement during a campaign event in Manhattan on Thursday.

‘We also know that this is the art of the deal,’ Mamdani said before adding, ‘We know that in a moment when New Yorkers are looking for an answer to the authoritarianism that we’re seeing from Washington, D.C., they don’t want the continuation of making City Hall into an embassy of that same administration.’

Adams has aligned with Trump since he was elected in November, visiting both Mar-a-Lago and the White House. Trump’s Justice Department dropped bribery, wire fraud and conspiracy charges against Adams earlier this year. 

Gov. Kathy Hochul, D-N.Y., weighed removing Adams from office following a slew of City Hall resignations after Adams’ case was dropped. Hochul has since endorsed Mamdani’s campaign, although Mamdani has yet to endorse Hochul’s re-election campaign. 

Pressure had been mounting since Mamdani won the Democratic primary for Adams or Cuomo to drop out of the race to consolidate support against Mamdani.

‘The mayor put his own personal ambition and ego aside to make sure he’s doing everything he can to make sure that New York remains New York,’ Cuomo said Thursday.

Adams announced he was suspending his campaign in a video on Sunday, Sept. 28, prompting the leading mayoral candidates to sharpen their political jabs against each other.

Similar pressure from billionaires, including Red Apple Media CEO John Catsimatidis and hedge fund CEO Bill Ackman, has intensified this week for Sliwa to drop out of the race in order to clear a pathway to victory for Cuomo.

The Democratic nominee, who handily defeated Cuomo in the primary, elicited Adams’ own words against the former governor in the days after he suspended his re-election campaign.

‘Even hearing Eric Adams, the way that he described Andrew Cuomo as a snake and a liar, is something that I’ve heard from a number of New Yorkers in wanting to turn that page,’ Mamdani said.

While Adams and Cuomo have had their fair share of disagreements, the Democrats agreed on Thursday that Mamdani should not become the next mayor of New York City. Adams addressed his own criticism of Adams during the announcement Thursday. 

‘He called me names. But you know what? Now it’s time to fight for the family, and I’m going to fight for the family with Andrew Cuomo as the next mayor of the city of New York,’ Adams said. 

The latest Fox News survey, conducted Oct. 10-14, ahead of the first general election debate last week, revealed that Mamdani has a substantial lead in the race. According to the poll, Mamdani has a 21-point lead among New York City registered voters with 49% of voters backing Mamdani, while 28% go for Cuomo and 13% favor Sliwa.

Mamdani also rose above the 50% threshold among likely voters, garnering 52% support, while Cuomo picked up 28%, and Sliwa received just 14%.

But as Mamdani, ever the social media-savvy candidate, warned his followers on Wednesday, it was Cuomo who was the favorite to win the nomination just weeks before the Democratic primary.

By consolidating support with New York City Comptroller Brad Lander, and cross-endorsing each other to topple Cuomo through ranked-choice voting, Mamdani pulled off the political upset that has since landed him on the national stage.

This post appeared first on FOX NEWS

President Donald Trump called off his meeting in Budapest, Hungary, with Russian President Vladimir Putin because he didn’t see enough progress toward peace — although a future summit hasn’t been ruled out, according to the White House. 

While Trump and Putin spoke over the phone Oct. 16, plans for the meeting were scrapped after Secretary of State Marco Rubio’s call with Russian Foreign Minister Sergey Lavrov Tuesday.

Trump ‘feels as though, unfortunately, from the Russian side as of late, he has not seen enough interest in enough action in terms of moving the ball forward toward peace,’ White House press secretary Karoline Leavitt told reporters Thursday. ‘And so a meeting between these two leaders is not completely off the table. I think the president and the entire administration hopes that one day that can happen again, but we want to make sure that there’s a tangible positive outcome out of that meeting, and that it’s a good use of the president’s time.’ 

Trump also has signaled in recent days that his patience has worn thin with Russia, and his administration slapped stringent sanctions on Russia’s two largest oil companies Wednesday. 

Specifically, the sanctions freeze all U.S.-linked assets from the two companies and bar U.S. citizens from engaging in any business with them. 

In response, Putin called the sanctions an ‘unfriendly act,’ and warned that global oil prices could increase as a result. However, he also said that the sanctions would not majorly impact Moscow’s economy. 

While Trump routinely has said in recent months that he has pleasant conversations with Putin, he’s also voiced frustration at the lack of progress made as he’s sought to mediate an end to the conflict. Trump also said Tuesday that he didn’t want to have a ‘wasted meeting’ with Putin in Hungary. 

‘The president wants to see action, not just talk,’ Leavitt said. ‘And I think the president is extremely motivated by the success of his peace deal in the Middle East to get things done, and he wants this war to come to an end. He’s been saying it now for nine months, being in office, and he’s grown increasingly frustrated with the lack of progress from both sides of this war.’ 

Trump met with Ukrainian President Volodymyr Zelenskyy Friday, and NATO Secretary-General Mark Rutte Wednesday to address ongoing negotiations to end the conflict. 

On Wednesday, Trump told reporters the meeting with Putin ‘didn’t feel right,’ and explained why he wasn’t interested in arming Ukraine with Tomahawk missiles like he’d previously suggested he might. 

‘There is a tremendous learning curve with the Tomahawk. It’s a very powerful weapon, very accurate weapon,’ Trump said Wednesday. ‘And maybe that’s what makes it so complex. But it will take a year. It takes a year of intense training to learn how to use it, and we know how to use it. And we’re not going to be teaching other people. It will be just too far out into the future.’

Meanwhile, Trump has voiced skepticism recently about whether Ukraine can win against Russia.

‘They could still win it. I don’t think they will, but they could still win it,’ Trump told reporters Monday.

The Associated Press contributed to this report. 

This post appeared first on FOX NEWS

Two federal judges admitted that members of their staff used artificial intelligence to prepare court orders over the summer that contained errors.

The admissions, which came from U.S. District Judge Julien Xavier Neals in New Jersey and U.S. District Judge Henry Wingate in Mississippi, came in response to an inquiry by Sen. Chuck Grassley, R-Iowa, who chairs the Senate Judiciary Committee.

Grassley described the recent court orders as ‘error-ridden.’

In letters released by Grassley’s office on Thursday, the judges said the rulings in the cases, which were not connected, did not go through their chambers’ usual review processes before they were released.

The judges both said they have since adopted measures to improve how rulings are reviewed before they are posted.

Neals said in his letter that a June 30 draft decision in a securities lawsuit ‘was released in error – human error – and withdrawn as soon as it was brought to the attention of my chambers.’

The judge said a law school intern used OpenAI’s ChatGPT to perform legal research without authorization or disclosure that he also said was contrary to the chamber’s policy and relevant law school policy.

‘My chamber’s policy prohibits the use of GenAI in the legal research for, or drafting of, opinions or orders,’ Neals wrote. ‘In the past, my policy was communicated verbally to chamber’s staff, including interns. That is no longer the case. I now have a written unequivocal policy that applies to all law clerks and interns.’

Wingate said in his letter that a law clerk used Perplexity ‘as a foundational drafting assistant to synthesize publicly available information on the docket,’ adding that releasing the July 20 draft decision ‘was a lapse in human oversight.’

‘This was a mistake. I have taken steps in my chambers to ensure this mistake will not happen again,’ the judge wrote.

Wingate had removed and replaced the original order in the civil rights lawsuit, declining at the time to give an explanation but saying it contained ‘clerical errors.’

Grassley had requested that the judges explain whether AI was used in the decisions after lawyers in the respective cases raised concerns about factual inaccuracies and other serious errors.

‘Honesty is always the best policy. I commend Judges Wingate and Neals for acknowledging their mistakes and I’m glad to hear they’re working to make sure this doesn’t happen again,’ Grassley said in a statement.

‘Each federal judge, and the judiciary as an institution, has an obligation to ensure the use of generative AI does not violate litigants’ rights or prevent fair treatment under the law,’ the senator continued. ‘The judicial branch needs to develop more decisive, meaningful and permanent AI policies and guidelines. We can’t allow laziness, apathy or overreliance on artificial assistance to upend the Judiciary’s commitment to integrity and factual accuracy. As always, my oversight will continue.’

Lawyers have also faced scrutiny from judges across the country over accusations of AI misuse in court filings. In response, judges have issued fines or other sanctions in several cases over the past few years.

Reuters contributed to this report.

This post appeared first on FOX NEWS

A federal judge struck down a Biden-era rule that expanded federal anti-discrimination measures to transgender healthcare, writing that the Department of Health and Human Services (HHS) ‘exceeded its authority by implementing regulations redefining sex discrimination and prohibiting gender identity discrimination.’

The ruling from Judge Louis Guirola Jr. of the U.S. District Court for the Southern District of Mississippi came after a coalition of 15 Republican-led states sued over the matter, according to The Hill.

‘When Biden-era bureaucrats tried to illegally rewrite our laws to force radical gender ideology into every corner of American healthcare, Tennessee stood strong and stopped them,’ Tennessee Attorney General Jonathan Skrmetti said in a statement following the ruling. ‘Our fifteen-state coalition worked together to protect the right of healthcare providers across America to make decisions based on evidence, reason, and conscience.’

‘This decision restores not just common sense but also constitutional limits on federal overreach, and I am proud of the team of excellent attorneys who fought this through to the finish,’ he added.

Skrmetti’s office said the U.S. District Court for the Southern District of Mississippi held that HHS ‘exceeded its authority when it issued a rule in May 2024 redefining Title IX’s prohibition against discrimination ‘on the basis of sex’ — which Congress incorporated into the ACA through Section 1557 — to include gender identity.’

‘HHS’s 2024 rule represented a disturbing federal intrusion into the States’ traditional authority to regulate healthcare and make decisions about their own Medicaid programs. Specifically, the rule would have prohibited healthcare facilities from maintaining sex-segregated spaces, required certain healthcare providers to administer unproven and risky procedures for gender dysphoria, and forced states to subsidize those experimental treatments through their Medicaid programs,’ it continued. ‘In vacating the rule, Judge Louis Guirola determined that when Congress passed Title IX in 1972, ‘sex’ meant biological sex and that federal agencies cannot unilaterally rewrite laws decades later to advance political agendas.’

The states involved in the lawsuit were Tennessee, Mississippi, Alabama, Georgia, Indiana, Kansas, Kentucky, Louisiana, Nebraska, Ohio, Oklahoma, South Carolina, South Dakota, Virginia, and West Virginia.

The rule was first created under the administration of former President Barack Obama in 2016, before President Donald Trump reversed it in his first term and then former President Joe Biden reversed it again, The Hill reported. 

Guirola’s ruling said HHS ‘exceeded its authority by implementing regulations redefining sex discrimination and prohibiting gender identity discrimination.’ 

The judge vacated the rule universally, but the rule had already been prevented from going into effect. It has been stayed since July 2024, according to Bloomberg Law. 

This post appeared first on FOX NEWS